Dr. Ivan Cubas, MD

Dr. Cubas practices at Endoscopy Center of Chula Vista in Chula Vista, California.

Dr. Cubas' NPI, 1447464912, was assigned on May 10, 2007. Dr. Cubas graduated from Cayetano Heredia University in 1999. Dr. Cubas holds California license C55825.

Dr. Cubas' primary practice is Endoscopy Center of Chula Vista, at 681 Third Avenue, Suite B, Chula Vista, CA 91910. The practice phone is (619) 425-2150.

Dr. Cubas' primary practice is Endoscopy Center of Chula Vista in Chula Vista, California. Dr. Cubas is also affiliated with Sharp Chula Vista Medical Center. The medical group on file is Emergency and Acute Care Medical Corporation. Dmand AI also links Dr. Cubas to 1 more hospital, 2 group practices and clinics, 1 physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cubas practices, 6 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Cubas' primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Cubas is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Cubas' licenses on file in 4 states: California, North Dakota, Colorado and Michigan.

Dmand AI lists acid reflux, acute gastroduodenitis, cirrhosis of the liver, colonoscopy, gastroduodenitis, gastroenteritis, gastrointestinal bleeding and hemorrhoids among the conditions Dr. Cubas treats.

CMS data shows 273 Medicare services from Dr. Cubas across 8 procedure codes in 2024, for 162 Medicare patients. Medicare paid $27,471 for them.

CMS counts 162 Medicare patients who saw Dr. Cubas in 2024. The largest group is 65 to 74, with 102 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 69% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cubas' median patient age at 70, with 53% women.

In 2024, Dr. Cubas wrote 1,019 Medicare Part D claims for 360 patients. 81% of them were for generic drugs. CMS names the drug for 906 of them, across 12 drugs with 11 or more claims each, at $85,458 in total drug cost. In 2023, CMS named 1,354 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Cubas for performance year 2024, reported as part of a group. Dr. Cubas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 157 procedures of colonoscopy by Dr. Cubas, more than 90% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Cubas.

Dmand AI links Dr. Cubas to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Crohn Disease, Gastroparesis and Non-alcoholic Fatty Liver Disease. Open Payments lists research payments to Dr. Cubas that name 1 trial.

CMS Open Payments shows 325 general payments to Dr. Cubas from 26 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 69% of the total. Boston Scientific Corporation paid the most, $2,582. It also lists 2 research payments totaling $2,772 from 2019 to 2020, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Cubas, most recently CMS Stage 1 EHR in 2013.

Dr. Cubas graduated from Cayetano Heredia University in 1999. Dr. Cubas is a member of ACG.

Dr. Cubas is in network with 18 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Medica. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.